A molecular evaluation of surplus cervical samples found the GynTect DNA methylation assay delivered substantially lower positivity than p16/Ki-67 dual staining in women with abnormal cytology. In the reported cohort of 1,000 women (PAP III or greater), GynTect produced a 27.7% positivity rate versus 88.3% for dual staining. The study suggests the methylation panel is more selective, with positivity increasing monotonically with cytology severity—17.0% in LSIL-equivalent categories and rising to 65.0% in high-grade groups. Within HPV16/18-positive subgroups, dual staining again marked far more cases positive (94.8%) than GynTect (38.4%). For screening programs balancing sensitivity and overtreatment, the comparative performance could inform triage pathways when the goal is to reduce false positives and unnecessary procedures while preserving risk stratification.